Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Context: Glucagon-like peptide-1 (GLP-1) agonists control postprandial glucose and lipid excursion in type 2 diabetes; however, the mechanisms are unclear. Objective: To determine the mechanisms of postprandial lipid and glucose control with lixisenatide (GLP-1 analog) in type 2 diabetes. Design: Randomized, double-blind, cross-over study. Setting: Centre for Diabetes, Endocrinology, and Research, Royal Surrey County Hospital, Guildford, United Kingdom. Patients: Eight obese men with type 2 diabetes [age, 57.3 ± 1.9 years; body mass index, 30.3 ± 1.0 kg/m2; glycosylated hemoglobin, 66.5 ± 2.6 mmol/mol (8.2% ± 0.3%)]. Interventions: Two metabolic studies, 4 weeks after lixisenatide or placebo, with cross-over and repetition of studies. Main Outcome Measures: Study one: very-low-density lipoprotein (VLDL) and chylomicron (CM) triacylglycerol (TAG) kinetics were measured with an IV bolus of [2H5]glycerol in a 12-hour study, with hourly feeding. Oral [13C]triolein, in a single meal, labeled enterally derived TAG. Study two: glucose kinetics were measured with [U-13C]glucose in a mixed-meal (plus acetaminophen to measure gastric emptying) and variable IV [6,6-2H2]glucose infusion. Results: Study one: CM-TAG (but not VLDL-TAG) pool-size was lower with lixisenatide (P = 0.046). Lixisenatide reduced CM [13C]oleate area under the curve (AUC)60–480min concentration (P = 0.048) and increased CM-TAG clearance, with no effect on CM-TAG production rate. Study two: postprandial glucose and insulin AUC0–240min were reduced with lixisenatide (P = 0.0051; P < 0.05). Total glucose production (P = 0.015), rate of glucose appearance from the meal (P = 0.0098), and acetaminophen AUC0–360min (P = 0.006) were lower with lixisenatide than with placebo. Conclusions: Lixisenatide reduced [13C]oleate concentrations, derived from a single meal in CM-TAG and glucose rate of appearance from the meal through delayed gastric emptying. However, day-long CM production, measured with repeated meal feeding, was not reduced by lixisenatide and decreased CM-TAG concentration resulted from increased CM-TAG clearance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. (A) Plasma TAG, (B) TRL-TAG, (C) VLDL-TAG, and (D) CM-TAG concentrations (mmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). Lixisenatide or placebo injection was self-administered at −270 minutes. The results are presented as mean ± SEM. Black arrows indicate hourly meals; narrow gray arrows, the meal labeled with [1,1,1 13C3]triolein; and wide gray arrows, the bolus of [1,1,2,3,3 2H5]glycerol administered at the start of steady-state. *P < 0.05.](https://figures.cochat.ai/paper-figures/2f725e3e462e4851823a86516f02b58b/lixisenatide-reduces-chylomicron-triacylglycerol-by-increased-clearance-figure-1.jpg)
![Figure 2. (A) CM [13C]oleate concentration (µmol/L) at fasting (−240 minutes) and after meal drinks at 1-hour intervals (−240 to 480 minutes) at the end of 4 weeks of treatment with either lixisenatide (white circles) or placebo (black circles) (study one). [13C]oleate was mixed with the third meal (−120 minutes). The lixisenatide or placebo injection was self-administered at −270 minutes. (B) FCR of VLDL-TAG and CM-TAG (pools per day). (C) Production rate of VLDL-TAG and CM-TAG (mg/d/kg body weight). The results are presented as mean ± SEM. *P < 0.05.](https://figures.cochat.ai/paper-figures/31fce818570d49d3a34ec870852a3ba9/lixisenatide-reduces-chylomicron-triacylglycerol-by-increased-clearance-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Whyte et al. showed that a four-week treatment with lixisenatide reduced chylomicron (CM)-TG pool-size and [13C] oleate concentrations, and increased CM-TG clearance without affecting CM-TG production rate.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [187]
In the citing paper
“These data lead the authors to conclude that the decreased CM-TG concentration may result from increased clearance rather than decreased production of lipoproteins [187].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [187]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Pearson, T. C., Guthrie, D. L., Simpson, J., Chinn, S., Barosi, G., Ferrant, A., Lewis, S. M., & Najean, Y. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08411.x · Cited by 321
Metabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes
Kashyap, S. R., Bhatt, D. L., Wolski, K., Watanabe, R. M., Abdul-Ghani, M., Abood, B., Pothier, C. E., Brethauer, S., Nissen, S., Gupta, M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1596 · Cited by 286
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Eberly, L. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1077 · Cited by 226
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Xiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164
Mekki, N., Christofilis, M. A., Charbonnier, M., Atlan-Gepner, C., Defoort, C., Juhel, C., Borel, P., Portugal, H., Pauli, A. M., Vialettes, B., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.1.5397 · Cited by 151
Lorenz, M., Pfeiffer, C., Steinsträßer, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 149
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143
Sharrett, A. R., Chambless, L. E., Heiss, G., Paton, C. C., & Patsch, W. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.12.2122 · Cited by 143
Mero, N., Malmström, R., Steiner, G. A., Taskinen, M., & Syvänne, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00364-0 · Cited by 131
Vella, A., Shah, P., Basu, R., Basu, A., Holst, J. J., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.4.611 · Cited by 119
Duez, H., Lamarche, B., Valéro, R., Pavlic, M., Proctor, S., Xiao, C., Szeto, L., Patterson, B. W., & Lewis, G. F. (2008) · Circulation · doi:10.1161/circulationaha.107.739888 · Cited by 115
Mekki, N. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.184 · Cited by 109
Andreozzi, F., Raciti, G. A., Nigro, C., Mannino, G. C., Procopio, T., Davalli, A. M., Beguinot, F., Sesti, G., Miele, C., & Folli, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0985-7 · Cited by 102
Alam, S., Stolinski, M., Pentecost, C., Boroujerdi, M. A., Jones, R. H., Sonksen, P. H., & Umpleby, A. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031036 · Cited by 97
Self-citationEstimation of the rate of appearance in the non-steady state with a two-compartment model
Mari, A. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.263.2.e400 · Cited by 92
Postprandial lipid metabolism: effects of dietary fatty acids
Williams, C. M. (1997) · Proceedings of The Nutrition Society · doi:10.1079/pns19970068 · Cited by 85
Owens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Vergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Sberna, A.-L., Petit, J.-M., Degrace, P., & Demizieux, L. (2018) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310990 · Cited by 75
Vetter, M. L., Wadden, T. A., Teff, K. L., Khan, Z. F., Carvajal, R., Ritter, S., Moore, R. H., Chittams, J. L., Iagnocco, A., Murayama, K., et al. (2015) · Diabetes · doi:10.2337/db14-0558 · Cited by 71
Maki, K. C., McKenney, J. M., Farmer, M. V., Reeves, M. S., & Dicklin, M. R. (2009) · Nutrition Journal · doi:10.1186/1475-2891-8-22 · Cited by 68
Give the Receptor a Brake: Slowing Gastric Emptying by GLP-1
Tong, J., & D’Alessio, D. (2014) · Diabetes · doi:10.2337/db13-1764 · Cited by 63
Shojaee-Moradie, F., Ma, Y., Lou, S., Hovorka, R., & Umpleby, A. M. (2013) · Diabetes · doi:10.2337/db13-0935 · Cited by 60
Self-citationChai, W., Fu, Z., Aylor, K. W., Barrett, E. J., & Liu, Z. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00205.2016 · Cited by 51
Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects
Cersosimo, E., Gastaldelli, A., Cervera, A., Wajcberg, E., Sriwijilkamol, A., Fernandez, M., Zuo, P., Petz, R., Triplitt, C., Musi, N., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2146 · Cited by 50
Yamazaki, S., Satoh, H., & Watanabe, T. (2014) · Endocrinology · doi:10.1210/en.2013-2157 · Cited by 49
SCHREZENMEIR, J., KEPPLER, I., FENSELAU, S., WEBER, P., BIESALSKI, H. K., PROBST, R., LAUE, C., ZUCHHOLD, H. D., PRELLWITZ, W., & BEYER, J. (1993) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1993.tb35721.x · Cited by 49
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s45379 · Cited by 42
Dane‐Stewart, C. A., Watts, G. F., Barrett, P. H. R., Stuckey, B. G. A., Mamo, J. C. L., Martins, I. J., & Redgrave, T. G. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01731.x · Cited by 42
Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
Asmar, A., Asmar, M., Simonsen, L., Madsbad, S., Holst, J. J., Hartmann, B., Sorensen, C. M., & Bülow, J. (2017) · Physiological Reports · doi:10.14814/phy2.13073 · Cited by 41
Shojaee-Moradie, F., Jackson, N. C., Jones, R. H., Mallet, A. I., Hovorka, R., & Umpleby, A. M. (1996) · Journal of Mass Spectrometry · doi:10.1002/(sici)1096-9888(199609)31:9<961::aid-jms359>3.0.co;2-h · Cited by 38
Åhrén, B., Gautier, J., Berria, R., Stager, W., Aronson, R., & Bailey, C. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12290 · Cited by 33
Estimating postprandial glucose fluxes using hierarchical Bayes modelling
Haidar, A., Potocka, E., Boulet, B., Umpleby, A. M., & Hovorka, R. (2012) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2012.01.010 · Cited by 14
Self-citationMoore, M. C., Werner, U., Smith, M. S., Farmer, T. D., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00354.2013 · Cited by 12
Adiels, M., Larsson, T. P., Sutton, P., Taskinen, M., Borén, J., & Fielding, B. A. (2010) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.4422 · Cited by 11
Self-citationA novel method for measuring intestinal and hepatic triacylglycerol kinetics
Sun, F., Stolinski, M., Shojaee‐Moradie, F., Lou, S., Ma, Y., Hovorka, R., & Umpleby, A. M. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00105.2013 · Cited by 9
Self-citationMeasurement of endogenous and exogenous triacylglycerol kinetics in the fed and fasted states
Sun, F., Stolinski, M., Shojaee‐Moradie, F., & Umpleby, A. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350482 · Cited by 3
Self-citation
Research works printed but not linked: 2
- Distiller L, Ruus PE Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients. Diabetes. 2008; 57: A154– A155.
- Becker RHA, Ruus P, Liu YH, Kapitza C Restoration of insulin release with lixisenatide in patients with type 2 diabetes. Diabetologia. 2010; 53:S339.
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“(c, f) Effects of GLP-1 receptor agonists (exenatide, lefthand bars [56]; liraglutide, right-hand bars [57], centre bars [58]) on triacylglycerol (c) and apo B48 (f) levels in individuals with type 2 diabetes following a fat-rich meal (relative to placebo treatment).”
BackgroundClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Metadata
- Authors
- Whyte, M. B., Shojaee-Moradie, F., Sharaf, S. E., Jackson, N. C., Fielding, B., Hovorka, R., Mendis, J., Russell-Jones, D., & Umpleby, A. M.
- Affiliations
- University of Surrey (GB)
- Faculty of Health and Medical Sciences, University of Surrey, Guildford, United Kingdom
- University of Cambridge (GB)
- Corresponding author
- Whyte, Martin B
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-09-11
- Volume
- 104
- Issue
- 2
- Pages
- 359-368
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6300412
- OpenAlex
- W2891142526
- Cited by
- 32
- References
- 49
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 1
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, GLP-1 receptor agonists, chylomicron clearance, postprandial lipemia, type 2 diabetes, postprandial blood glucose, gastric emptying, glucose kinetics, hypertriglyceridemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Chylomicrons, Diabetes Mellitus, Type 2, Double-Blind Method, Gastric Emptying, Humans, Hypoglycemic Agents, Male, Metabolic Clearance Rate, Middle Aged, Peptides, Triglycerides, Treatment Outcome, Cross-Over Studies, Postprandial Period
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.